#USA #BioLife Solutions #Bothell #Cold Chain Logistics #SAVSU

BioLife Solutions Sells its evo Cold Chain Logistics Subsidiary

On October 7, 2025, BioLife Solutions, Inc. (Nasdaq: BLFS), a premier provider of cell processing tools and services for the cell and gene therapy (CGT) market, announced the successful sale of its cold chain logistics subsidiary, SAVSU Technologies, LLC. This transaction took place with Peli BioThermal, a renowned leader in temperature-controlled logistics solutions, for a total of $25.5 million in cash, pending certain adjustments.

Strategic Objectives of the Sale

Roderick de Greef, Chairman and CEO of BioLife Solutions, highlighted that this divestment aligns with the company's strategy to streamline its product offerings. By focusing on high-margin recurring revenue, BioLife aims to enhance its overall operational efficiency while driving shareholder value. The sale allows the company to concentrate its resources on core areas that generate sustainable growth for investors.

De Greef stated, "This divestiture streamlines our product portfolio as well as our operations while focusing resources on creating shareholder value through high-margin recurring revenue. We are delighted that a respected leader in cold chain logistics recognizes the value of the SAVSU evo technology."

The SAVSU division was known for its cutting-edge technology that ensured the integrity of biological materials during transportation. This capability is vital in the CGT industry, especially for maintaining the viability of cell and gene therapies, which often have stringent storage and transport requirements.

Implications for BioLife Solutions

The sale marks a significant shift in BioLife Solutions' business model, allowing them to better allocate financial and operational resources. With the cold chain logistics component now part of Peli BioThermal, BioLife can focus on its primary mission: developing innovative solutions for the CGT market. The divestiture is expected to enhance the company's agility in responding to the evolving landscape of bioproduction and therapy commercialization.

BioLife Solutions specializes in providing critical tools and services that facilitate the collection, development, manufacturing, and distribution of biological materials—key components in the emerging therapies facilitated by the company’s technologies. Investors and stakeholders can expect BioLife to strive for greater achievements within its core capabilities following this transition.

Looking Ahead

As part of its commitment to maximizing shareholder value, BioLife Solutions will continue to monitor market needs and adjust its focus accordingly. The company is optimistic about its future endeavors and aims to remain at the forefront of innovations within the biotechnology space.

To learn more about BioLife Solutions and their services, interested parties are encouraged to visit their official website at www.biolifesolutions.com, or follow them on social media platforms such as LinkedIn and X.

Forward-Looking Statements

It's essential to note that certain comments made regarding future expectations may constitute forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995. These statements involve numerous risks and uncertainties that can affect actual results. The company advises stakeholders to review filings made with the U.S. Securities and Exchange Commission for a detailed examination of potential risks and uncertainties.

The decision to sell SAVSU represents a pivotal moment for BioLife Solutions, illustrating their commitment to optimizing their operations and enhancing their core offerings to better serve the global market for cell and gene therapies.